This study assesses how patients' perceivedeatingbehaviorsevolve in response to different stimuli after initiating aGLP-1receptor agonist.
In addition to their weight loss benefits,GLP-1RAs also act on neural circuits involved in appetite, impulse control, and reward.
Key pointsGLP-1drugs can transform the health of people with obesity, quiet "food noise," and may level the weight-loss playing field. Research on the drugs' mental healtheffectsis mixed. Experts worry widespread use could fuel sizeism andeatingdisorders. Psychologists are helpingGLP-1patients develop healthybehaviorsand manage body image, identity, and relationship changes.
Elucidating the relationship betweenGLP-1analogs and ingestivebehaviorcould reveal additional parameters which contribute to their anti-obesityeffects.
We provide a targeted synthesis of recent developments in the field of glucagon-like peptide-1 (GLP-1) neurobiology, highlighting studies which have advanced our understanding of howGLP-1signaling modulateseating, and identify open questions and future challenges we believe still need to be addressed to aid the prevention and/or treatment of obesity.
Conclusion Together, these results suggest thatGLP-1receptor agonists may promote substantial weight loss through improved perceived regulation ofeatingbehavior, supporting a state in which physiological cues have a greater influence on food intake than emotional, external, sensory, and situational cues.
HowGLP-1ChangesEatingBehaviorand Food Choices Clinical studies show thatGLP‑1medications are associated with reduced hunger, increased satiety, smaller meal sizes, and longer gaps between meals.
